Get startedLog in
    Picture of Swedish Orphan Biovitrum AB (publ) logo

    SOBI — Swedish Orphan Biovitrum AB (publ) News Story

    0.000.00%
    se flag iconLast trade - 00:00
    HealthcareBalancedLarge CapHigh Flyer
    All News

    Brief: Sweden's SOBI Says Positive Topline Results From Pivotal Phase 3 Reduce 2 Study Of Pozdeutinurad In Gout

    Picture of Swedish Orphan Biovitrum AB (publ) logoSwedish Orphan Biovitrum AB (publ)
    21/05/2026 21:32
    May 22 (Reuters) - Swedish Orphan Biovitrum AB (publ) SOBIV.ST:

SWEDISH ORPHAN BIOVITRUM: POSITIVE TOPLINE RESULTS FROM PIVOTAL PHASE 3 REDUCE 2 STUDY OF POZDEUTINURAD IN GOUT

SWEDISH ORPHAN BIOVITRUM - BOTH DOSES OF ONCE-DAILY POZDEUTINURAD (AR882) MET PRIMARY EFFICACY ENDPOINT OF SUA REDUCTION AT MONTH 6 VERSUS PLACEBO

Source text: ID:nWkr5twYgz

Further company coverage: SOBIV.ST

 ((reuters.briefs@thomsonreuters.com;))

    Recent news on Swedish Orphan Biovitrum AB (publ)

    See all news